Raji Shameem, MD, discusses first-line treatment planning for pancreatic adenocarcinoma including clinical trial eligibility alongside standard chemotherapy options.
Raji Shameem, MD
Advertisement
Raji Shameem, MD is a medical oncologist and hematologist at Orlando Health Cancer Institute.
Articles by Raji Shameem, MD
Raji Shameem, MD, discusses considerations for selecting between available chemotherapy regimens for patients with advanced pancreatic cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5